Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System

Cytotherapy

Volumn 16, Issue 8, 2014, Pages 1048-1058

  Hanley, Patrick J ^a,b   Mei, Zhuyong ^a   Durett, April G ^a   da Graca Cabreira Harrison, Marie ^c   Klis, Mariola ^a   Li, Wei ^a   Zhao, Yali ^a   Yang, Bing ^d   Parsha, Kaushik ^d   Mir, Osman ^d   Vahidy, Farhaan ^d   Bloom, Debra ^e   Rice, R Brent ^f   Hematti, Peiman ^e   Savitz, Sean I ^d   Gee, Adrian P ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f Terumo BCT   (United States)

Author keywords

Cell culture expansion; Good manufacturing practices; Mesenchymal stromal cells; Quantum; Stroke

Indexed keywords

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOREACTOR; BONE MARROW; BRAIN ISCHEMIA; CARTILAGE CELL; CELL ACTIVITY; CELL COUNT; CELL DIFFERENTIATION; CELL EXPANSION; CELL LINEAGE; CELL THERAPY; COLONY FORMATION; CONTROLLED STUDY; MALE; MESENCHYMAL STROMA CELL; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; QUANTUM CELL EXPANSION SYSTEM; RAT; ANIMAL; BIOLOGICAL THERAPY; BONE MARROW CELL; CULTURE TECHNIQUE; CYTOLOGY; GENETICS; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION;

RATTUS;

ANIMALS; BIOREACTORS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINEAGE; CELL- AND TISSUE-BASED THERAPY; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RATS;

EID: 84903814743     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.01.417     Document Type: Article

References (30)

1. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008, 8:726-736.
2. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
3. Philippe B., Luc S., Valerie P.B., Jerome R., Alessandra B.R., Louis C. Culture and use of mesenchymal stromal cells in phase I and II clinical trials. Stem Cells Int 2010, 2010:503593.
4. Newman R.E., Yoo D., LeRoux M.A., Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009, 8:110-123.
5. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002, 99:8932-8937.
6. Reiser J., Zhang X.Y., Hemenway C.S., Mondal D., Pradhan L., La Russa V.F. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Exp Opin Biol Ther 2005, 5:1571-1584.
7. Battiwalla M., Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 2009, 11:503-515.
8. Campagnoli C., Roberts I.A., Kumar S., Bennett P.R., Bellantuono I., Fisk N.M. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001, 98:2396-2402.
9. Malgieri A., Kantzari E., Patrizi M.P., Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med 2010, 3:248-269.
10. Gotherstrom C., Ringden O., Westgren M., Tammik C., Le Blanc K. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 2003, 32:265-272.
11. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
12. Vidal M.A., Walker N.J., Napoli E., Borjesson D.L. Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue. Stem Cells Dev 2012, 21:273-283.
13. Connick P., Kolappan M., Patani R., Scott M.A., Crawley C., He X.L., et al. The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 2011, 12:62.
14. Sabatino M., Ren J., David-Ocampo V., England L., McGann M., Tran M., et al. The establishment of a bank of stored clinical bone marrow stromal cell products. JTranslation Med 2012, 10:23.
15. Hanley P.J., Mei Z., da Graca Cabreira-Hansen M., Klis M., Li W., Zhao Y., et al. Manufacturing mesenchymal stromal cells for phase I clinical trials. Cytotherapy 2013, 15:416-422.
16. Bieback K., Kinzebach S., Karagianni M. Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells Int 2011, 2010:193519.
17. Sensebe L., Bourin P., Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 2011, 22:19-26.
18. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nature Med 1999, 5:309-313.
19. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., et al. Tcell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. JBiomed Sci 2005, 12:47-57.
20. Nold P., Brendel C., Neubauer A., Bein G., Hackstein H. Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem Biophys Res Commun 2013, 430:325-330.
21. Rojewski M.T., Fekete N., Baila S., Nguyen K., Furst D., Antwiler D., et al. GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device Quantum Cell Expansion system. Cell Transplant 2012, 22:1981-2000.
22. Schallmoser K., Strunk D. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. JVisual Exp 2009, 32:1523.
23. Friedenstein A.J., Deriglasova U.F., Kulagina N.N., Panasuk A.F., Rudakowa S.F., Luria E.A., et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974, 2:83-92.
24. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
25. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
26. Pileggi A. Mesenchymal stem cells for the treatment of diabetes. Diabetes 2012, 61:1355-1356.
27. Lee J.S., Hong J.M., Moon G.J., Lee P.H., Ahn Y.H., Bang O.Y. Along-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010, 28:1099-1106.
28. Jean-Francois Michiels M.E. Scaling up stem cells: utilizing a multiplate bioreactor to preserve the integrity of the culture. Genet Eng Biotechnol News 2013, 33:26.
29. Jones M., Varella-Garcia M., Skokan M., Bryce S., Schowinsky J., Peters R., et al. Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System. Cytotherapy 2013, 15:1323-1339.
30. Otsuru S., Hofmann T.J., Olson T.S., Dominici M., Horwitz E.M. Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. Cytotherapy 2013, 15:146-153.